Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
20.05.2011 14:30:00

Logos Technologies Joins Medidata Solutions Technology Partner Program

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced London-based Logos Technologies as a Medidata Technology Partner. An early-phase eSource data capture, trial management and clinical site automation specialist, Logos leveraged Medidata’s Web Services API to integrate data from its ALPHADAS® Phase I solution with Medidata Rave®, an industry-leading system for capturing, managing and reporting clinical research data. The completed integration enables the rapid transfer of Phase I data and metadata collected in ALPHADAS into Medidata Rave. Sponsors can benefit from Rave data management capabilities for Phase I trials and more easily view clinical data from all trial phases for a particular treatment in Rave.

ALPHADAS is a multi-study, schedule-driven, automated workflow system with staff and subject management tools, as well as barcoded sample tracking and management. It is designed to help sponsors and investigators around the world improve the speed, safety, quality and efficiency of Phase I trials, minimizing data queries while providing clean data in real time. A recent thorough QT study (TQT) study conducted at Spaulding Clinical Research in Westbend, Wis., showed that using ALPHADAS to collect and validate clinical data at the site produced virtually 100 percent accurate data. ALPHADAS also accepts patient data directly from clinical instrumentation, including vital sign systems, ECG devices and telemetry-based systems.

With this integration, sites can use ALPHADAS at the bedside, in the clinic and remotely, while sponsors benefit from a comprehensive view of a treatment’s trial data from all phases in one system, Medidata Rave. Moreover, with both the study metadata and study subject data captured in ALPHADAS rapidly moving to Rave, sponsors can take advantage of advanced Rave capabilities in data management, including easy query communication, coding and insightful reporting. The integration also enables sponsors using ALPHADAS for Phase I data capture to make use of Medidata Rave Safety Gateway, a configurable EDC-to-safety system interface that streamlines the reporting of serious adverse events by eliminating the need for duplicate data entry.

"This integration really is the best of both worlds. Sites use ALPHADAS, which significantly drives data quality and efficiencies, while sponsors capitalize on this streamlined access to clean data,” said Giles Wilson, CEO of Logos Technologies Inc. "This unique integration provides an automated workflow from bedside procedure direct to the sponsor and will bring significant benefits to our clients and the market as a whole, raising the bar and opening up unprecedented opportunities in early phase studies. We are thrilled to release this unique integration with Rave.”

Logos Technologies joins the innovative Medidata Technology Partner Program, which recognizes organizations with complementary technologies that support data sharing with Medidata products, providing clinical researchers a streamlined and enhanced research process utilizing a choice of advanced innovations.

"Phase I research comes with unique challenges and workflow, and we’re always looking for ways to help sponsors improve that part of the process, whether it’s through our products or partnerships,” said Glen de Vries, president of Medidata Solutions. "Integrating with Logos allows ALPHADAS users to transition Phase I research seamlessly into Medidata’s study management environment. Our joint customers will benefit from a rich set of data capture and management capabilities to handle their Phase I trials, as well as the ability to more easily view all study data in one system – Medidata Rave – for all phases of a study.”

About Logos Technologies Inc.

Logos Technologies Inc (www.logostechnologies.com) is a leading provider of world-class clinical trial solutions to pharmaceutical, biotechnology and clinical research organizations. ALPHADAS® is a proactive, eSource clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture. ALPHADAS is also available in specific modules, CTMS and sample tracking as well as a full EDC solution. It meets the changing demands and time sensitive nature of early phase trials while integrating with clinical and laboratory operations. It accelerates data throughput, and enhances data integrity.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from protocol development (Medidata Designer®), trial planning and management (Medidata Grants Manager®, Medidata CRO Contractor®), clinical portal (iMedidata), randomization and trial supply management (Medidata Balance), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), safety events capture (Medidata Rave Safety Gateway), clinical data capture and management (Medidata Rave®) to advanced reporting and analytics (Medidata Insights). Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!